Table 1. Demographic and clinical characteristics of the study cohort.
| Age at Diagnosis (median, IQR) | 45.5 (40–53) |
|---|---|
| Menopausal status | |
| Pre | 50 (68%) |
| Post | 24 (32%) |
| Histological subtype | |
| Ductal invasive carcinoma | 58 (78%) |
| Lobular invasive carcinoma | 12 (16%) |
| Mixed invasive carcinoma | 4 (6%) |
| Grade | |
| x/n.a | 16 (22%) |
| 1 | 2 (3%) |
| 2 | 29 (39%) |
| 3 | 27 (36%) |
| T size | |
| pT1 | 26 (35%) |
| pT2> | 48 (65%) |
| Lynphonode Status | |
| Negative | 17 (23%) |
| Positive | 57 (73%) |
| Ki67 | |
| Luminal A-like | 27 (36%) |
| Luminal B-like | 46 (62%) |
| n.a | 1 (1%) |
| Adjuvant Chemotherapy regimen | |
| Anthracycline containing | 32 (43%) |
| No chemotherapy | 27 (37%) |
| Other | 15 (20%) |
| Adjuvant endocrine treatment | |
| Aromatase inhibitors (AI) | 12 (16%) |
| LHRH + AI | 3 (4%) |
| Tamoxifen followed by AI | 5 (7%) |
| Tamoxifen (TAM) | 11 (15%) |
| LHRH + TAM | 40 (54%) |
| Random Clinical Trial | 3 (4%) |
| Relapse-free interval (mm, 95% CI) | 74.5 (62.0–97.7) |